Key result
Statins, fibrates, and niacin reduce sdLDL-C and shift LDL subclasses toward larger, less atherogenic particles.
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C). DATA SOURCES: Literature was obtained from MEDLINE (1989-September 2004) and references of selected articles. Key search terms included small-dense LDL-C and lipid-lowering drug therapy. DATA SYNTHESIS: Statins, fibrates, and niacin have demonstrated favorable effects on sdLDL-C, especially among patients with mixed dyslipidemia or hypertriglyceridemia. These effects include a reduction of sdLDL-C and/or a shift to the larger, less atherogenic LDL-C. CONCLUSIONS: Data suggest that statins, fibrates, and niacin are effective at reducing concentrations of sdLDL-C and possibly normalizing LDL-C subclasses.
No takes yet. Share an insight, caveat, or question.
Backes et al. (2005) conducted a review in Mixed dyslipidemia or hypertriglyceridemia. Lipid-lowering drug therapy (statins, fibrates, and niacin) was evaluated on Small-dense low-density lipoprotein cholesterol (sdLDL-C) concentration and LDL-C subclass shift. Statins, fibrates, and niacin effectively reduce small-dense LDL-C concentrations and shift LDL-C toward larger, less atherogenic subclasses in mixed dyslipidemia or hypertriglyceridemia.
Synapse has enriched 10 related papers. Consider them for comparative context: